NCT00051675已完成1 期
An Open-Label, Multi-Dose, Phase I, Dose-Escalating Study of a Subcutaneously Administered Human-Engineered Monoclonal Antibody, ING-1(heMAb), in Subjects With Advanced Adenocarcinomas
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 2
研究概览
简要总结
The purpose of this study is to evaluate the safety, immunogenicity, and tolerability of a monoclonal antibody administered subcutaneously in the treatment of advanced cancers of the ovary, breast, lung, prostate, colon or rectum that are either refractory to standard therapies or for which therapies that may potentially be of major benefit do not exist.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
CP-675,206 In Patients With Advanced MelanomaMalignant MelanomaNCT00086489AstraZeneca118
招募中
1 期
A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid TumorsAdvanced Solid TumorsNCT05688605Lepu Biopharma Co., Ltd.18
已完成
1 期
A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid TumorsAdvanced or Metastatic Solid TumorsNCT04843709Lepu Biopharma Co., Ltd.39
已完成
1 期
Study of the CD40 Agonistic Monoclonal Antibody APX005MUrothelial CarcinomaMSI-HHead and Neck CancerCancerMelanomaNSCLCNCT02482168Apexigen America, Inc.43
已完成
1 期
MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.Solid TumorsNCT02503774MedImmune LLC192